Study of Serum Hepcidin in Hereditary Hemolytic Anemias

REFERENCES

• El-Beshlawy A, Kaddah N, Moustafa A, Mouktar G, Youssry I. Screening for β-thalassaemia carriers in Egypt: significance of the osmotic fragility test. East Mediterr Health J. 2007;13(4):780–786.
   PubMedGoogle Scholar
• El-Beshlawy A, Manz C, Naja M, . Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol. 2008;87(7):545–550.
   PubMed Web of Science ®Google Scholar
• Agarwal MB. Advances in management of thalassemia. Indian J Pediatr. 2009;76(2):177–184.
   PubMed Web of Science ®Google Scholar
• Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806–7810.
   PubMed Web of Science ®Google Scholar
• Kemna EH, Kartikasari AE, van Tits LJ, Pickkers P, Tjalsma H, Swinkels DW. Regulation of hepcidin: insights from biochemical analyses on human serum samples. Blood Cells Mol Dis. 2008;40(3):339–346.
   PubMed Web of Science ®Google Scholar
• Merle U, Fein E, Gehrke SG, Stremmel W, Kulaksiz H. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology. 2007;148(6):2663–2668.
   PubMed Web of Science ®Google Scholar
• Nicolas G, Chauvet C, Viatte L, . The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037–1044.
   PubMed Web of Science ®Google Scholar
• Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002;100(10):3776–3781.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005;105(4):1803–1806.
   PubMed Web of Science ®Google Scholar
• Ganz T, Olbina G, Girelli E, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292–4297.
   PubMed Web of Science ®Google Scholar
• Geerts I, Vermeersch P, Joosten E. Evaluation of the first commercial hepcidin ELISA for the differential diagnosis of anemia of chronic disease and iron deficiency anemia in hospitalized geriatric patients. ISRN Hematol. 2012;2012:567491.
   PubMedGoogle Scholar
• Ingelfinger JA, Ed. Biostatistics in Clinical Medicine, 3rd ed. New York: MacGraw-Hill Inc., 1994.
   Google Scholar
• Kemna E, Tjalsma H, Laarakkers C, Nemeth E, Willems H, Swinkels D. Novel urine hepcidin assay by mass spectrometry. Blood. 2005;106(9):3268–3270.
   PubMed Web of Science ®Google Scholar
• Ruivard M, Lainé F, Ganz T, . Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J Hepatol. 2009;50(6):1219–1225.
   PubMed Web of Science ®Google Scholar
• Papanikolaou G, Tzilianos M, Christakis JI, . Hepcidin in iron overload disorders. Blood. 2005;105(10):4103–4105.
   PubMed Web of Science ®Google Scholar
• Kearney SL, Nemeth E, Neufeld EJ, . Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer. 2007;48(1):57–63.
   PubMed Web of Science ®Google Scholar
• Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem. 2007;53(4):620–628.
   PubMed Web of Science ®Google Scholar
• Kattamis A, Papassotiriou I, Palaiologou D, . The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica. 2006;91(6):809–812.
   PubMed Web of Science ®Google Scholar
• Origa R, Galanello R, Ganz T, . Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica. 2007;92(5):583–588.
   PubMed Web of Science ®Google Scholar
• Kroot JJ, Laarakkers CM, Kemna EH, Biemond BJ, Swinkels DW. Regulation of serum hepcidin levels in sickle cell disease. Haematologica. 2009;94(6):885–887.
   PubMed Web of Science ®Google Scholar
• Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 2006; 55(6):667–74.
   PubMed Web of Science ®Google Scholar
• Donagh KT, Nienhuis AW. The thalassemia in hematology of infancy and childhood. In: Nathan DG, Orkin SH, Oski FA, Ginsburg D, Eds. Nathan and Oski’s Hematology of Infancy and Childhood, 4th ed. Philadelphia: W.B. Saunders. 1998:832–856.
   Google Scholar
• Nemeth E. Hepcidin in β-thalassemia. Ann NY Acad Sci. 2010; 1202:31–35.
   PubMed Web of Science ®Google Scholar
• Camberlein E, Zanninelli G, Détivaud L, . Anemia in β-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression. Haematologica 2008; 93(1):111–115.
   PubMed Web of Science ®Google Scholar
• Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood. 2007;110(3):1048–1054.
   PubMed Web of Science ®Google Scholar
• Tanno T, Miller JL. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol. 2010;2010:358283. Epub 2010 May 11.
   PubMedGoogle Scholar
• Gardenghi S, Ramos P, Marongiu MF, . Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. J Clin Invest. 2010;120(12):4466–4477.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Payen E, Negre O, . Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010; 467(7313): 318–322.
   PubMed Web of Science ®Google Scholar
• Li H, Rybicki AC, Suzuka SM, . Transferrin therapy ameliorates disease in B-thalassemic mice. Nat Med. 2010;16(2):177–182.
   PubMed Web of Science ®Google Scholar
• Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications. J Hepatol. 2011;54(1):173–181.
   PubMed Web of Science ®Google Scholar